Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...

The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s (TSE: 4568) VANFLYTA® ...

Daiichi Sankyo has announced the dosage of the first subject in the randomised Phase III QuANTUM-Wild trial of oral Vanflyta ...

Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical ...

Daiichi Sankyo begins patient dosing in QuANTUM-Wild phase 3 trial of Vanflyta in newly diagnosed FLT3-ITD negative AML: Tokyo Thursday, December 12, 2024, 12:00 Hrs [IST] The fir ...

(RTTNews) - Moleculin Biotech, Inc. (MBRX), Wednesday announced the preliminary activity of Annamycin in heavily pretreated, relapsed/refractory acute myeloid leukemia or AML patients who had ...

Despite treatment advancements with the introduction of HDMTX and rituximab, up to half of patients will have disease relapse, and 10%–15% may have primary refractory disease.

A Phase 3 trial of uproleselan failed to improve overall survival in relapsed/refractory AML, though it may benefit primary ...

The ocean's biodiversity is a key source of marine-derived compounds, fueling pharmaceutical innovations and drug discovery ...

Kura Oncology (KURA) and Kyowa Kirin provided encouraging clinical data from KOMET-007, a Phase 1 dose-escalation trial of ziftomenib, a highly ...

A phase 3 trial of uproleselan in relapsed/refractory acute myeloid leukemia failed to meet the primary overall survival end ...

The world's oceans represent a vast and largely untapped source of biodiversity, offering a high probability for the ...